Teva Pravachol Exclusivity Loss Raises Bristol’s Stakes For Switch
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb has more to gain from an Rx-to-OTC switch of the cholesterol-lowering drug Pravachol (pravastatin) if an FDA decision allowing multiple generics on the market in April 2006 is upheld